GM Hikaru Nakamura holds a 42.33% loss on uniQure (QURE) shares in his TipRanks investment portfolio. The U.S. Chess Champion purchased 300 shares at $30.83 on November 3, 2024, for a total of $9,249. The position is now valued at $5,334, a loss of $3,915.

GM Hikaru Nakamura

GM Hikaru Nakamura

Candidates player, streamer, investor

[At the time of purchase] Stock fell 70%+ initially on news with the FDA regarding AMT-130. Skeptical that there won’t be a reversal as there is a big unmet need regarding Huntington’s Disease. This could play out very similarly to REPL and SRPT

uniQure is a Dutch biopharma company developing gene therapies for serious neurological conditions, including Huntington’s disease. QURE shares are down 25.49% year-to-date after FDA declarations labeled uniQure’s Huntington’s disease gene therapy a failed product. Concerns over trial methodology, including skull drilling procedures, have added to the decline.

Nakamura (2810) is a five-time U.S. Chess Champion and two-time World Championship Candidate. He partners with [TipRanks on a public Stream Portfolio]https://www.tipranks.com/screener/gmhikaru){:target=”_blank”}, where followers can track and contribute to his investment decisions in real time. Nakamura’s overall portfolio holds a total return of 3.8%, outperforming the S&P 500 by 1.4%, with nine of 18 transactions in profit.

Photo: Michal Walusza